In patients undergoing elective percutaneous coronary intervention (PCI), glucagon-like peptide-1 (GLP-1) infusion did not reduce the incidence of PCI-associated myocardial infarction (PMI), according to study results published in the American Heart Journal.
The results indicated that GLP-1 infusion did not influence the rate of major adverse cardiovascular and cerebrovascular events (MACCE) at 12 months post-PCI.
The study included patients undergoing elective PCI (N=192) who were randomly assigned 1:1 to an intravenous infusion of either GLP-1 at 1.2 pmol/kg/min or matched 0.9% saline placebo before and during the procedure. The primary end point was PMI, defined as a rise of ≥five times the upper limit of normal (280 ng/L), measured by six-hour cardiac troponin I (cTnI). Secondary outcomes including cTnI rise and MACCE at 12 months.
The results indicated no difference in the rate of PMI between patients in the GLP-1 group (9.3%; n=8) and patients in the placebo group (9.8%; n=9); P =1.
The researchers found no difference in median cTnI between the GLP-1 group (20 ng/L; 95% CI, 0-58.5) compared with placebo (9.5 ng/L; 95% CI, 0-88.5); P =.25. In addition, there was no difference in MACCE at 12 months, with a rate of 7.3% (n=7) in the GLP-1 group and 9.4% (n=9) in the placebo group; P=.61.
“Although our study has shown that GLP-1 does not protect against lethal [ischemia-reperfusion] injury in the elective PCI setting, there may still be clinical utility for an agent that reduces ischemic dysfunction and myocardial stunning,” the researchers wrote.
Disclosures: One study author disclosed being employed by several pharmaceutical companies. Please refer to the original text for full list of author disclosures.
Giblett JP, Clarke S, Zhao T, et al. The role of glucagon-like peptide 1 loading on periprocedural myocardial infarction during elective PCI (GOLD-PCI) study: a randomized, placebo-controlled trial. Am Heart J. 2019;215:41-51.